Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne, Ph.D.,
Chief Executive Officer, will present a corporate and pipeline overview
at Cowen and Company’s 36th Annual Health Care Conference on
March 8, 2016 at 10 a.m. ET at the Boston Marriott Copley Place Hotel in
Boston, MA.
A webcast of the presentation will be available in the Investors section
of the Company’s website, www.catabasis.com,
and will be archived for 30 days following the presentation.
About CAT-1004
CAT-1004 is an oral small molecule that has the potential to be a
disease-modifying therapy for all patients affected by Duchenne muscular
dystrophy (DMD or Duchenne), regardless of the underlying mutation.
CAT-1004 inhibits NF-kB, a protein that is activated in Duchenne and
drives inflammation and fibrosis, muscle degeneration and suppresses
muscle regeneration. In animal models of DMD, CAT-1004 inhibited NF-kB,
reduced muscle degeneration and improved muscle regeneration and
function, and beneficial effects were observed in skeletal, diaphragm
and cardiac muscle. The FDA has granted orphan drug, fast track and rare
pediatric disease designations and the European Commission has granted
orphan medicinal product designation to CAT-1004 for the treatment of
DMD. We have previously reported safety, tolerability and reduction in
NF-kB activity in Phase1 trials in adults. We are currently conducting
the MoveDMDSM trial of CAT-1004 in 4-7 year-old boys affected
by Duchenne. From Part A of the MoveDMD trial, we have reported that all
three doses of CT-1004 tested were generally well tolerated with no
safety signals observed. Pharmacokinetic results demonstrated CAT-1004
average plasma exposure levels consistent with those previously observed
in adults at which inhibition of NF-kB was observed.
About CAT-2054
CAT-2054 is an oral small molecule with a novel mechanism of action
targeting Sterol Regulatory Element-Binding Protein (SREBP) being
developed for serious lipid disorders such as hypercholesterolemia. By
inhibiting SREBP, a master regulator of lipid metabolism in the body,
CAT-2054 has the potential to significantly reduce LDL-C; it may also
have beneficial effects on other metabolic parameters such as
triglycerides, glucose and liver fat. This profile may differentiate
CAT-2054 from currently approved therapies for hypercholesterolemia and
others in development. Catabasis is developing CAT-2054 to be used on
top of statins in patients who cannot reach their LDL-C goal with
statins alone. We are currently conducting a Phase 2a trial of CAT-2054
in addition to high intensity statin therapy in patients with
hypercholesterolemia, and have previously reported positive top-line
Phase 1 data. We are also conducting research studies to support the
potential of CAT-2054 in non-alcoholic steatohepatitis (NASH).
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. We have product
candidates in both rare diseases and serious lipid disorders. Our SMART
(Safely Metabolized And Rationally Targeted) linker drug discovery
platform enables us to engineer molecules that simultaneously modulate
multiple targets in a disease. We are applying our SMART linker platform
to build an internal pipeline of product candidates for rare diseases
and plan to pursue partnerships to develop additional product
candidates. For more information on the Company's drug discovery
platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302006343/en/
Copyright Business Wire 2016